Abivax SA (ABVX) | Stock Overview & Key Data
Abivax SA Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €132.00 on January 12, 2026
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Abivax SA
ABVX
|
7.61B Large-cap | -4.54% | -14.08% | -20.62% | -18.33% | -26.00% | 1,368.91% | 434.91% | 184.92% | 1,317.50% | 310.87% | 310.87% |
|
Nanobiotix
NANO
|
1.39B Large-cap | 3.58% | -27.34% | 8.48% | 64.63% | 67.58% | 587.64% | 529.63% | 150.41% | 87.73% | 393.55% | 393.55% |
|
Dbv Technologies
DBV
|
1.02B Large-cap | 12.32% | -4.78% | -7.80% | 2.24% | -2.45% | 89.31% | -17.08% | -70.89% | -94.37% | -62.38% | -62.38% |
|
TheraVet S.A
ALVET
|
N/A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -89.74% | -98.11% | -99.02% | -99.02% | -99.02% | -99.02% |
|
Inventiva S.A
IVA
|
980.10M Mid-cap | -4.11% | -32.02% | -36.99% | -12.10% | -19.26% | 17.12% | -17.79% | -71.83% | -58.75% | -58.75% | -58.75% |
|
Medincell S.A
MEDCL
|
831.60M Mid-cap | -0.86% | 1.61% | 25.88% | 25.88% | 25.88% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% |
Ownership & Short Interest
Calculate Your Abivax SA Investment Returns
Long-Term Investment Performance Analysis
Abivax SA stock price in Jul 2016 was €4.13, A €1,000.00 lump sum investment in Abivax SA made 9 years ago would be worth approximately €20,605.33 today, representing a exceptional return of 1,960.53%. This translates to an annualized return (CAGR) of 35.71%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ABVX's 52-week high and low?
- In the last 52 weeks, Abivax SA reached a high of €132.00 (on January 12, 2026) and a low of €5.12 (on June 23, 2025).
- What is the market cap and P/E ratio for ABVX?
- Curious about Abivax SA's size and valuation? Its market capitalization stands at 7.61B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.88, and the forward P/E (looking ahead) is -30.74.
- Does ABVX pay dividends? If so, what's the yield?
- As for dividends, Abivax SA isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Abivax SA's main competitors or similar companies to consider before investing?
When looking at Abivax SA, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Nanobiotix
NANO1.39B Healthcare Biotechnology 587.64% 529.63% Dbv Technologies
DBV1.02B Healthcare Biotechnology 89.31% -17.08% TheraVet S.A
ALVETN/A Healthcare Biotechnology -89.74% -98.11% Inventiva S.A
IVA980.10M Healthcare Biotechnology 17.12% -17.79% Medincell S.A
MEDCL831.60M Healthcare Biotechnology 23.51% 23.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Abivax SA? (e.g., ROE, Debt/Equity)
- To get a sense of Abivax SA's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -135.58%, the Debt to Equity ratio from the most recent quarter is 7.05, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ABVX?
- Looking at Abivax SA's growth, its revenue over the trailing twelve months (TTM) was €5M. Compared to the same quarter last year (YoY), quarterly revenue grew by -55.40%, and quarterly earnings saw a YoY growth of N/A.
- How much of ABVX stock is held by insiders and institutions?
- Wondering who owns Abivax SA stock? Company insiders (like executives and directors) hold about 1.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 45.76%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.